Pharmaceuticals company Aurobindo Pharma announced Q3FY25 results Revenue from Operations increased by 8.5% YoY to Rs 7,979 crore with growth across the businesses. US formulations revenue decreased by 2.3% YoY to Rs 3,671 crore (USD 435 million). Europe formulations revenue increased by 22.7% YoY to Rs 2,121 crore (EUR 236 million). Growth Markets revenue increased by 39.3% YoY to Rs 873 crore (USD 104 million). ARV revenue increased by 71.2% YoY to Rs 307 crore (USD 36 million). API revenue decreased by 1.6% YoY to Rs 1,006 crore (USD 119 million). EBITDA before R&D; stood at Rs 2,056 crores with a margin of 25.8%. EBITDA before Forex and Other Income stood at Rs 1,628 crore; EBITDA margin at 20.4%. Research & Development (R&D; including depreciation) spend was Rs 450 crore, 5.6% of revenue. Received final approval for 8 ANDAs (including 1 ANDA previously tentatively approved, now received the final approval) from the USFDA. Net Profit for the period stood at Rs 846 crore. Basic & Diluted EPS stood at Rs 14.56 per share. Nithyananda Reddy, Vice-Chairman and Managing Director, said: " We are pleased to report our highest-ever quarterly revenue, driven by volume growth from our diverse and expanding product portfolio coupled with new launches. This performance highlights our resilience. Looking ahead, we are enhancing our manufacturing capabilities and ramping up our specialty and injectable business. With these initiatives, we expect notable profitability improvements and are well-positioned to sustain growth and meet our objectives for the year." Result PDF